Seborrheic dermatitis is a chronic inflammatory skin disorder characterized by scaly, erythematous, and itchy skin in sebum-rich areas of the body (e.g., scalp, face, upper chest). The severity of disease can range from mild dandruff to widespread patches of red, itchy, inflamed skin lesions, which place a social and psychological burden on patients. Topical antifungals are the entrenched treatment; topical corticosteroids are common second-line options, although safety and tolerability concerns render them suboptimal medications for longer-term symptom management. Novel nonsteroidal therapies, including topical phosphodiesterase-4 inhibitors (i.e., Arcutis Biotherapeutics’ topical roflumilast), are in clinical development. If efficacious, they stand to capitalize on the unmet need for additional effective and safe therapies in this space.
Executive Insights provides indication-specific market intelligence with world-class epidemiology, keen insight into current treatment paradigms, biotherapeutic pipelines, key clinical unmet needs, and competitive landscapes, supported by primary and secondary research. This solution provides succinct insights to any biopharma function or business professional looking to quickly grasp a new indication of interest.